Seikagaku’s current research is split between two specific areas of expertise—new products based on our long pioneering involvement with Glycosaminoglycans (GAGs), a part of the broad spectrum of glycoconjugates, and development of novel products to serve a wider area of joint disease extending beyond, that now served by the ARTZ® -series products. With a keen sense of urgency, we have fortified our system for intensive timeline management. We are also expanding our product pipeline through codevelopment and licensing activities while simultaneously accelerating in-house R&D programs. Our triple emphasis on in-house development, licensing and collaborative research and alliances with other institutions is the best way to assure a consistent launch of the new products that will bring profits to sustain further development and growth.

Seikagaku aims to pump 20% of net sales back into R&D, which is conducted by a staff of 183, or one-third of the total number of employees. This level is sufficient to sustain projects now under way and we are hiring more as needed to sustain our licensing and exploratory research.

Trends in R&D Expenses

Trends in R&D Personnel